Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery
Public ClinicalTrials.gov record NCT02014402. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomized, Double-blind, Phase II Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgeries
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This purpose of this clinical trial was to study the safety and efficacy of Topical Thrombin (Human) Grifols as an add-on treatment to help stop bleeding during vascular, liver, soft tissue, and spinal surgical procedures.
Study identification
- NCT ID
- NCT02014402
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 181 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Oct 31, 2015
- Completion
- Oct 31, 2015
- Last update posted
- Jun 13, 2017
2013 – 2015
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 805 | Tucson | Arizona | 85712 | — |
| 602 | Los Angeles | California | 90048 | — |
| 700, 801 | Pasadena | California | 91105 | — |
| 803 | Boulder | Colorado | 80303 | — |
| 908 | Hartford | Connecticut | 06102 | — |
| 601 | Washington D.C. | District of Columbia | 20007 | — |
| 507 | Gainesville | Florida | 32611 | — |
| 501, 901 | Jacksonville | Florida | 32216 | — |
| 604 | Evanston | Illinois | 60208 | — |
| 804 | Lexington | Kentucky | 40509 | — |
| 905 | Baltimore | Maryland | 21201 | — |
| 902 | Jackson | Mississippi | 39216 | — |
| 800 | Las Vegas | Nevada | 89144 | — |
| 600 | New York | New York | 10029 | — |
| 606 | Poughkeepsie | New York | 12601 | — |
| 508 | Chapel Hill | North Carolina | 27599 | — |
| 503 | Fort Worth | Texas | 76107 | — |
| 900 | Houston | Texas | 77024 | — |
| 605 | Salt Lake City | Utah | 84132 | — |
| 802 | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02014402, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 13, 2017 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02014402 live on ClinicalTrials.gov.